Merarchi Myriam, Jung Young Yun, Fan Lu, Sethi Gautam, Ahn Kwang Seok
Faculty of Pharmacy, University of Paris Descartes, 75006 Paris, France.
Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore.
Biomedicines. 2019 Jul 19;7(3):53. doi: 10.3390/biomedicines7030053.
For the last couple of decades, natural products, either applied singly or in conjunction with other cancer therapies including chemotherapy and radiotherapy, have allowed us to combat different types of human cancers through the inhibition of their initiation and progression. The principal sources of these useful compounds are isolated from plants that were described in traditional medicines for their curative potential. Leelamine, derived from the bark of pine trees, was previously reported as having a weak agonistic effect on cannabinoid receptors and limited inhibitory effects on pyruvate dehydrogenase kinases (PDKs). It has been reported to possess a strong lysosomotropic property; this feature enables its assembly inside the acidic compartments within a cell, such as lysosomes, which may eventually hinder endocytosis. In this review, we briefly highlight the varied antineoplastic actions of leelamine that have found implications in pharmacological research, and the numerous intracellular targets affected by this agent that can effectively negate the oncogenic process.
在过去几十年里,天然产物无论是单独应用还是与包括化疗和放疗在内的其他癌症治疗方法联合使用,都使我们能够通过抑制癌症的起始和进展来对抗不同类型的人类癌症。这些有用化合物的主要来源是从传统医学中有治疗潜力记载的植物中分离出来的。源自松树树皮的利拉明,此前报道对大麻素受体有微弱激动作用,对丙酮酸脱氢酶激酶(PDKs)有有限抑制作用。据报道它具有很强的溶酶体趋向性;这一特性使其能够在细胞内的酸性区室(如溶酶体)内聚集,最终可能阻碍内吞作用。在本综述中,我们简要强调利拉明在药理学研究中具有的多种抗肿瘤作用,以及该药物可有效对抗致癌过程的众多细胞内靶点。